This is a field-notes piece, not an interview. It synthesizes patterns from conversations with eight to ten engineers, scientists, and project leads who have worked process analytical technology projects on both pharmaceutical and bulk-chemicals sites. No quote here is attributed to a single named source; the cases are composites. We write the patterns down because they recur across companies, geographies, and chemistries, and because the same hardware vendor often sells the same probe into both industries and is surprised by how differently the project goes.
The headline finding is uninteresting on its face: pharma and chemicals do PAT in different cultures. The interesting part is which differences matter for a project plan, and which differences are stylistic and can be ignored. We list the ones that matter.
What “done” means
In a pharmaceutical project, done is a documented state. The analyzer is qualified, the model is validated against ICH Q14, the SOPs are in place, the operators are trained against a curriculum, and the audit trail is reviewed. There is a date on which the work transitioned from project to operations, and that date is the date the validation report was signed. The instrument can be running flawlessly for months before that date and the project is not done; the instrument can be misbehaving on the date and the project is done as long as the documentation is consistent. This is not cynical, it is the regulatory contract: the manufacturer commits to the documented state.
In a chemicals project, done is an operational state. The analyzer is on the line, the loop is closed, the alarm rates are tolerable, and the unit operations group has stopped escalating. There is rarely a single date. There is rarely a signed report. There is a moment where the project manager stops attending the weekly review and that is generally considered the handover. The same probe, the same model, the same physics; a different definition of completion.
Practitioners who move between the two industries tend to underestimate how much project effort is allocated to documentation in pharma and how much is allocated to operational stabilization in chemicals. The total effort is comparable; the allocation is not.
Who owns the model
In pharma, the chemometric model is owned by a regulated function - quality, analytical development, or a dedicated PAT group reporting into one of those. The model is a controlled document; changes require change control. A new minor revision can take weeks. A new calibration range can take a quarter.
In chemicals, the model is owned by whichever engineer built it, which is often a process engineer or an automation engineer rather than a chemometrician. Changes are made when needed and committed to whichever version-control practice the site happens to follow (which on a surprising number of sites is “the .mat file is on a shared drive”). A new minor revision can take an afternoon.
The pharma practice is slower and produces a model with a known provenance. The chemicals practice is faster and produces a model that works on the line but is difficult to reproduce two years after the engineer who built it has left. Neither practice is wrong for its industry. Practitioners who try to import pharma’s change control into a chemicals site report being treated as bureaucratic; practitioners who try to import chemicals’ agility into a pharma site report being treated as reckless.
What “validation” buys you
Pharma validates because the regulator requires it. A model with a written validation report has been demonstrated to perform within stated tolerances on independent samples, against a reference method, across the range claimed by the model. The validation produces the right to use the model for release decisions. It does not produce reliability under drift; that requires ongoing performance verification, which is a separate document.
Chemicals validates because the engineering manager requires it, when they do, and the bar is the model has been on the line long enough to convince me it works. There is rarely a written validation report and almost never an independent test against a reference method outside the calibration set. The result is a model that may be working well or may be performing poorly in ways nobody has measured; the operating culture compensates with frequent human checks and lab follow-up rather than with documented statistical performance.
When chemicals sites adopt pharma-style validation - which a handful are doing as their downstream customers move toward continuous manufacturing - they typically discover that the validation work surfaces real model weaknesses, not just paperwork. This is consistent with what scaling PAT across multiple plants tends to surface: the rigor pays back in the second deployment.
Alarm tolerance
A chemicals analyzer that produces three nuisance alarms per shift is annoying but tolerable; operators acknowledge them and move on. A pharma analyzer that produces three nuisance alarms per shift is a deviation generator: each alarm is potentially a logged event that has to be investigated and trended. The same false-positive rate that is background noise in a chemicals control room is an organizational problem in a pharma suite.
The implication for the project is large. A model with a 5 % false-positive rate on the alarm threshold is shippable on a chemicals line. The same model is unshippable on a pharma line until the threshold is retuned or the model is improved. Practitioners who move between industries report being surprised by this consistently.
The probe is the probe
What is not different: the physics of the measurement. A Raman probe sees what a Raman probe sees regardless of the regulatory environment. The vibrational modes of acetaminophen are the vibrational modes of acetaminophen. NAMUR-NE107 diagnostics on a field device behave the same whether the device is on a pharma reactor or a chemicals reactor. The instrument vendors who try hardest to claim industry-specific advantage in their hardware are usually selling the same hardware to both industries; the difference is in the software stack, the documentation package, and the application-engineering hours allocated to the project.
This is worth saying because purchasing groups on both sides occasionally fear that the “wrong industry” version of a vendor’s product will not work for them. In our observation it almost always does work; what differs is whether the documentation package fits the buyer’s quality system and whether the vendor’s application engineers have done your specific application before.
Continuous manufacturing collapses the gap
The one place the two cultures are visibly converging is pharma’s continuous manufacturing programs, which inherit chemicals’ operational mindset - keep the line running, tune the model when needed, monitor drift continuously - while still satisfying the pharma documentation contract. Practitioners working in CM report that the cultural compromise is harder than the technical work. The instruments are familiar. The decision rights are not.
What to do with this
If you are a chemicals practitioner about to start a pharma project: plan twice the documentation effort and half the iteration speed. The work is the same; the cycle time is not.
If you are a pharma practitioner about to start a chemicals project: plan twice the operational stabilization effort and a quarter of the documentation effort. The chemometrics is the same; the change-control overhead is not.
If you are an instrument vendor selling into both: have two documentation packages and one piece of hardware. Most vendors who have been doing this for a decade already do, and the ones who do not lose the deal at the last moment to the ones who do.